BCL2 and central nervous system cancer: A similar result was observed in mice that contained preestablished, patient-derived glioma cells, where the decrease in tumor flux in NSC-treated mice was more substantial when NSCs were modified to overexpress Bcl-2 (Supplementary Figure 4).